IEZZA, MIRIAM
 Distribuzione geografica
Continente #
AS - Asia 155
EU - Europa 87
NA - Nord America 68
AF - Africa 3
SA - Sud America 3
OC - Oceania 1
Totale 317
Nazione #
US - Stati Uniti d'America 67
CN - Cina 57
SG - Singapore 51
IT - Italia 38
HK - Hong Kong 19
KR - Corea 17
NL - Olanda 16
FI - Finlandia 8
VN - Vietnam 8
RU - Federazione Russa 6
DE - Germania 5
GB - Regno Unito 4
BR - Brasile 3
CI - Costa d'Avorio 3
AT - Austria 2
CH - Svizzera 2
FR - Francia 2
ID - Indonesia 2
IE - Irlanda 2
AU - Australia 1
CA - Canada 1
IN - India 1
PL - Polonia 1
SE - Svezia 1
Totale 317
Città #
Singapore 48
Hefei 27
Ashburn 26
Hong Kong 19
Seoul 17
Bologna 13
Santa Clara 7
Boardman 6
Hanoi 4
Abidjan 3
Helsinki 3
Lappeenranta 3
Milan 3
Tongling 3
Bern 2
Cagliari 2
Dublin 2
Grand Forks 2
Jakarta 2
Nanjing 2
Pavia 2
Turku 2
Vado Ligure 2
Amsterdam 1
Atlanta 1
Belo Horizonte 1
Casalecchio di Reno 1
Chicago 1
Concord 1
Duque de Caxias 1
Frankfurt am Main 1
Guangzhou 1
Hangzhou 1
Ho Chi Minh City 1
Hyderabad 1
Jinhua 1
Lang Son 1
London 1
Los Angeles 1
Munich 1
Ninh Bình 1
Nuremberg 1
Prineville 1
Rostock 1
Springfield 1
Sydney 1
São Paulo 1
Taiyuan 1
Thái Nguyên 1
Tianjin 1
Vancouver 1
Vienna 1
Wroclaw 1
Wuhan 1
Xingtai 1
Zhengzhou 1
Totale 233
Nome #
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 58
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 57
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 51
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study 48
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 47
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study 40
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 38
Totale 339
Categoria #
all - tutte 1.423
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.423


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20236 0 0 0 0 1 0 0 0 0 1 0 4
2023/202428 0 0 0 0 0 5 3 5 2 8 4 1
2024/2025272 7 20 28 15 26 12 11 8 6 26 41 72
2025/202633 33 0 0 0 0 0 0 0 0 0 0 0
Totale 339